U.S. pharma large copyright scrapped two experimental weight loss tablets last yr—a once-each day capsule, lotiglipron, due to elevated liver enzymes along with a twice-day by day tablet, danuglipron, resulting from powerful Unintended effects—but CEO Albert Bourla has stated the company is determined to “Participate in and win” during the